Table 2.
The actuarial 5-year overall survival, disease-free survival, locoregional progression-free survival, local progression-free survival, regional progression-free survival and metastasis-free survival rates in the intensity-modulated radiotherapy-treated and helical tomotherapy-treated groups
| Survival rate | IMRT (non-IGRT) | HT (IGRT) | 95 % CI | p value |
|---|---|---|---|---|
| 5-year OS | 47.5 % | 86.7 % | 0.53 to 0.64 | 0.015 |
| 5-year DFS | 39.3 % | 73.8 % | 0.40 to 0.74 | 0.146 |
| 5-year LRPFS | 49.8 % | 69.8 % | 0.37 to 0.77 | 0.104 |
| 5-year LPFS | 58.4 % | 85.2 % | 0.58 to 0.70 | 0.006 |
| 5-year RPFS | 81.2 % | 81.4 % | 0.62 to 0.72 | 0.653 |
| 5-year MFS | 82.6 % | 80.1 % | 0.62 to 0.72 | 0.892 |
Abbreviations: DFS disease-free survival, HT helical tomotherapy, IGRT image-guided radiotherapy, IMRT intensity-modulated radiotherapy, MFS metastasis-free survival, non-IGRT non-image-guided radiotherapy, LRPFS locoregional progression-free survival, LPFS local progression-free survival, OS overall survival, RPFS regional progression-free survival